Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 232 results
Filters: Author is Aga, Evgenia  [Clear All Filters]
Found 232 results.

Adult

Riddler SA, Aga E, Bosch RJ, et al. "Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy." J. Infect. Dis.. 2016;213(4):556-60.
Besson GJ, Lalama CM, Bosch RJ, et al. "HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy." Clin. Infect. Dis.. 2014;59(9):1312-21.
Connick E, Bosch RJ, Aga E, Schlichtemeier R, Demeter LM, Volberding P. "Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection." J. Acquir. Immune Defic. Syndr.. 2011;58(1):1-8.
Gay CL, Bosch RJ, Ritz J, et al. "Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy." J. Infect. Dis.. 2017;215(11):1725-1733.
Gandhi RT, Bosch RJ, Aga E, et al. "No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy." J. Infect. Dis.. 2010;201(2):293-6.
Volberding P, Demeter L, Bosch RJ, et al. "Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment." AIDS. 2009;23(15):1987-95.
Kumarasamy N, Aga E, Ribaudo HJ, et al. "Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230." Clin. Infect. Dis.. 2015;60(10):1552-8.
Wallis CL, Aga E, Ribaudo H, et al. "Drug susceptibility and resistance mutations after first-line failure in resource limited settings." Clin. Infect. Dis.. 2014;59(5):706-15.
Taiwo B, Gallien S, Aga E, et al. "Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy." J. Infect. Dis.. 2011;204(4):515-20.
Sereti I, Dunham RM, Spritzler J, et al. "IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection." Blood. 2009;113(25):6304-14.
Bartlett JA, Ribaudo HJ, Wallis CL, et al. "Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings." AIDS. 2012;26(11):1345-54.
J Kilby M, R Bucy P, Mildvan D, et al. "A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024)." J. Infect. Dis.. 2006;194(12):1672-6.

Pages